News

October 14, 2021

The Pharmaceutical Technology and BioPharm International editors host industry experts, highlighting trends and new technologies.

October 14, 2021

Avid Bioservices is building a viral vector development and manufacturing facility near its existing biologics manufacturing facility in California.

October 14, 2021

Enzyvant’s Rethymic is the first FDA approved treatment for congenital athymia.

October 14, 2021

Element’s acquisition of Nanosyn is the latest in a series of moves made to strengthen the company’s North American presence.

October 14, 2021

Roche has submitted a marketing authorization application to EMA for Ronapreve (casirivimab/imdevimab) as a treatment for COVID-19.

October 14, 2021

EMA has halted the rolling review of CureVac's COVID-19 candidate, CVnCoV, due to the company withdrawing from the process.

October 14, 2021

MHRA has awarded an ‘Innovation Passport’ to CellResearch for its umbilical cord lining stem cell therapy, CorLiCyte.

October 13, 2021

Smiths Detection has confirmed that the Bioflash air sampler can detect Beta, Gamma, Kappa, Delta, and Delta plus variants.

October 13, 2021

Pacira’s acquisition grants them access to Flexion’s pain management portfolio.

October 12, 2021

AstraZeneca reports that its combination antibody therapy, AZD7442, reduced chances of severe COVID-19 or death by as much as 67%.